Cerebral metabolism in patients with cognitive disorders: a combined MRS and PET study

Close metadata

Recommended articles:

Glymphatic dysfunction and sleep disorders: indirect effects on Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):7-12

Ginkgolide B: mechanisms of neurobiological effects, prospects for use in the therapy of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):22-27

Prevalence of cognitive impairment in older adults in the Russian Federation. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):5-11

Comparative characteristics of neuropsychological and neurometabolic changes in patients with Alzheimer’s disease and vascular cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):17-24

Impairment of attention and executive functions in chronic cerebrovascular disease and Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):25-32

Assessment of the significance of dilated perivascular spaces and nocture arterial hypertension in the development of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):33-40

Cognitive impairment in patients with arterial hypertension. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):41-48

EEG changes in patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):72-76

Drug-induced cognitive impairment and dementia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):77-85

Cognitive impairment in multiple system atrophy — exclusion criteria or an integral part of the clinical picture?. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):86-91

Objective. Magnetic resonance spectroscopy (MRS) allows studying the content of many metabolites in neural tissue in vivo. There are numerous studies devoted to the MRS data analysis in Alzheimer’s disease (AD), but their results are contradictory. Thus, it is rational to compare the data obtained with MRS and positron emission tomography (PET) with fluorodeoxyglucose (FDG), which allows evaluating the brain functional state. In this paper, the authors compared MRS data in AD and mild cognitive impairment (MCI) with the cerebral glucose metabolism changes according to FDG PET. Material and methods. Multivoxel proton MRS of the supraventricular area was performed in patients with AD (n=16) and MCI (n=14). The following metabolites ratios were evaluated: NAA/Cr, Cho/Cr, NAA/Cho (NAA — N-acetylaspartate, Cr — creatine, Cho — choline). All patients underwent neurological examination, assessment of cognitive status and PET with FDG. Results. A decrease in NAA/Cr and Cho/Cr ratios in the supraventricular white matter and medial cortex in both hemispheres was observed in AD patients. In the MCI group, NAA/Cr ratio were decreased only in left white matter adjusting to the parietal cortex. Positive correlations of NAA/Cr and Cho/Cr ratios with cognitive status, as well as the cerebral glucose metabolism rate according to the PET data in frontal, parietal, temporal and cingulate cortex were revealed. Conclusions. The decrease in the NAA/Cr ratio in the supraventricular white matter and the medial cortex in AD and the correlation of this index with the results of cognitive tests and cerebral glucose metabolism suggest that it can be of diagnostic significance, reflecting the severity of cognitive impairment. In this case, the NAA/Cr ratio should be evaluated taking into account the changes in concentrations of both metabolites (NAA and Cr) in dementia.

Keywords:

magnetic resonance spectroscopy

Alzheimer’s disease

cognitive impairment

N-acetylaspartate

choline

creatine

positron emission tomography

Authors:

Homenko Ju.G.

N. Bekhtereva Institute of the Human Brain of the Russian Academy of Science, St. Petersburg, Russia

Kataeva G.V.

Institut mozga cheloveka im. N.P. Bekhterevoĭ RAN, Sankt-Peterburg

Bogdan A.A.

N. Bechtereva Institute of the Human Brain, Russian Acsdemy of Sciences, St. Petersburg

Chernysheva E.M.

N. Bekhtereva Institute of the Human Brain, Russian Academy of Sciences, St.-Petersburg, Russia

Susin D.S.

N. Bekhtereva Institute of the Human Brain of the Russian Academy of Science, St. Petersburg, Russia

List of references:

Tabert M, Liu X, Doty R, Serby M, Zamora D, Pelton G, Marder K, Albers M, Stern Y, Devanand D. A 10-item smell identification scale related to risk for Alzheimer’s disease. Ann Neurol. 2005;58(1):155-160.
Verdile G, Fuller S, Atwood C, Lawsa S, Gandye S, Martins R. The role of beta amyloid in Alzheimer’s disease: still a cause of everything or the only one who got caught? Pharmacological Research. 2004;50:397-409.
Mathis C, Mason N, Lopresti B, Klunk W. Development of positron emission tomography β-amyloid plaque imaging agents. Semin Nucl Med. 2012;42(6):423-432. https://doi.org/10.1053/j.semnuclmed.2012.07.001
Trzepacz P, Yu P, Sun J, Schuh K, Case M, Witte M, Hochstetler H, Hake A. Alzheimer’s Disease Neuroimaging Initiative. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer’s dementia. Neurobiol Aging. 2014;35(1):143-151. https://doi.org/10.1016/j.neurobiolaging.2013.06.018
Magnetic Resonance Neuroimaging. Methods in Molecular Biology. Modo M, Bulte J, eds. Springer. 2011. https://doi.org/10.1007/978-1-61737-992-5_9
Barker PB, Bizzi A, De Stefano N, Gullapalli RP, Lin DM. Clinical MR Spectroscopy: Techniques and Applications. Cambridge University Press; 2009.
Haga KK, Khor YP, Farrall A, Wardlaw JM. A systematic review of brain metabolite changes, measured with 1H magnetic resonance spectroscopy, in healthy aging. Neurobiology of Aging. 2009;30:353-363. https://doi.org/10.1016/j.neurobiolaging.2007.07.005
Magnetic resonance spectroscopy. Tools for Neuroscience Research and Emerging Clinical Applications. Stagg C, Rothman D, eds. Elsevier. 2014.
Semenova NA, Akhadov TA, Petryaykin AV, Sidorin SS, Lukovenkov AV, Varfolomeev SD. Metabolic disorders and interrelations of metabolic processes in human frontoparietal cortex in severe traumatic brain injury. Single voxel 1H magnetic resonance spectroscopy study. Biokhimiya. 2012;77(4):493-500. (In Russ.)
Hetherington HP, Mason GF, Pan JW, Ponder SL, Vaughan JT, Twieg DB, Pohost GM. Evaluation of cerebral gray and white matter metabolite differences by spectroscopic imaging at 4.1T. Magn Reson Med. 1994;32(5):565-571. https://doi.org/10.1002/mrm.1910320504
Shiino A, Matsuda M, Morikawa S, Inubushi T, Akiguchi I, Handa J. Proton magnetic resonance spectroscopy with dementia. Surg Neurol. 1993;39(2):143-147. https://doi.org/10.1016/0090-3019(93)90093-g
Kantarci K, Petersen RC, Boeve BF. 1H-MR spectroscopy in common dementias. Neurology. 2004;63(8):1393-1398. https://doi.org/10.1212/01.wnl.0000141849.21256.ac
Wang H, Tan L, Wang HF, Liu Y, Yin RH, Wang WY, Chang XL, Jiang T, Yu JT. Magnetic Resonance Spectroscopy in Alzheimer’s Disease: Systematic Review and Meta-Analysis. J Alzheimers Dis. 2015;46(4):1049-1070. https://doi.org/10.3233/JAD-143225
Frederick BB, Satlin A,Yurgelun-Todd DA, Renshaw PF. In vivo proton magnetic resonance spectroscopy of Alzheimer’s disease in the parietal and temporal lobes. Biol Psychiatry. 1997;42(2):147-150. https://doi.org/10.1016/s0006-3223(97)00242-4
Bitsch A, Bruhn H, Vougioukas V, Stringaris A, Lassman H, Frahm J, Bruck W. Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am J Neuroradiol. 1999;20(9):1619-1627.
Jessen F, Block W, Traber F. Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology. 2000;55:5:684-688. http://www.ajnr.org/content/20/9/1619
Huang W, Alexander GE, Chang L, et al. Brain metabolite concentration and dementia severity in Alzheimer’s disease: a (1)H MRS study. Neurology. 2001;57(4):626-632. https://doi.org/10.1212/wnl.57.4.626
Pfefferbaum A, Adalsteinsson E, Spielman D, Sullivan EV, Lim KO. In vivo spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: effects of normal aging. Magn Reson Med. 1999;41(2):276-284. https://doi.org/10.1002/(sici)1522-2594(199902)41:2<276::aid-mrm10>3.3.co
Krishnan KR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, Perdomo C, Ieni JR, Rogers S. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer’s disease. Am J Psychiatry. 2003;160(11):2003-2011. https://doi.org/10.1176/appi.ajp.160.11.2003
Chantal S, Labelle M, Bouchard RW, Braun CM, Boulanger Y. Correlation of regional proton magnetic resonance spectroscopic metabolic changes with cognitive deficits in mild Alzheimer disease. Arch Neurol. 2002;59(6):955-962. https://doi.org/10.1001/archneur.59.6.955
Tumati S, Martens S, Aleman A. Magnetic resonance spectroscopy in mild cognitive impairment: systematic review and meta-analysis. Neurosci Biobehav Rev. 2013;37(10 Pt 2):2571-2586. https://doi.org/10.1016/j.neubiorev.2013.08.004
Zhang B, Ferman TJ, Boeve BF, Smith GE, Maroney-Smith M, Spychalla AJ, Knopman DS, Jack CR Jr, Petersen RC, Kantarci K.MRS in mild cognitive impairment: early differentiation of dementia with Lewy bodies and Alzheimer’s disease. J Neuroimaging. 2015;25(2):269-274. https://doi.org/10.1111/jon.12138
Kantarci K, Knopman DS, Dickson DW, Parisi JE, Whitwell JL, Weigand SD, Josephs KA, Boeve BF, Petersen RC, Clifford RJ. Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. Radiology. 2008;248(1):210-220. https://doi.org/10.1148/radiol.2481071590
Coutinho AMN, Porto FHG, Zampieri PF, Otaduy MC, Perroco TR, Oliveira MO, Nunes RF1, Pinheiro TL3, Bottino CMC2, Leite CC3, Buchpiguel CA. Analysis of the posterior cingulate cortex with [18F]FDG-PET and Naa/mI in mild cognitive impairment and Alzheimer’s disease: Correlations and differences between the two methods. Dement Neuropsychol. 2015;9(4):385-393. https://doi.org/10.1590/1980-57642015DN94000385
Medvedev SV, Skvortsova TYu, Krasikova RN. PET in Russia: positron emission tomography in clinic and physiology. SPb. 2008 (In Russ.)
Bogdan AA, Khomenko YuG, Kataeva GV, Trofimova TN. Principles of data grouping in assessment of human brain multivoxel spectroscopic studies. Luchevaya diagnostica I terapiya. 2016;4(7):15-19. (In Russ.)
Charlton RA, McIntyre DJ, Howe FA, Morris RG, Markus HS. The relationship between white matter brain metabolites and cognition in normal aging: The GENIE study. Brain Research. 2007;1164:108-116. https://doi.org/10.1016/j.brainres.2007.06.027
Allman JM, Tetreault NA, Hakeem AY, Manaye KF, Semendeferi K, Erwin JM, Park S, Goubert V, Hof PR. The von Economo neurons in fronto-insular and anterior cingulate cortex. Ann NY Acad Sci. 2011;1225:59-71. https://doi.org/10.1111/j.1749-6632.2011.06011.x
Talairach J, Tournoux P. Co-planar stereotactic atlas of the human brain: 3-dimensional proportional system: an approach to cerebral imaging. Thieme New-York. 1988.
Statistical Parametric Mapping. www.fil.ion.ucl.ac.uk/spm/
WFU PickAtlas. http://www.nitrc.org/projects/wfu_pickatlas/
Yakushev I, Landvogt C, Buchholz HG, Fellgiebel A, Hammers A, Scheurich A, Schmidtmann I, Gerhard A, Schreckenberger M, Bartenstein P. Choice of reference area in studies of Alzheimer’s disease using positron emission tomography with fluorodeoxyglucose-F18. Psychiatry Res. 2008;164(2):143-153. https://doi.org/10.1016/j.pscychresns.2007.11.004
Khomenko YuG, Bogdan AA, Kataeva GV, Chernysheva EM. Implementation of magnetic resonance spectroscopy in the examination of patients with cognitive impairment. Vestnik Sankt-Peterburgskogo Universiteta. Seriya 4. Fizika. Khimiya. 2016;3(1):82-89. (In Russ.)
Schuff N, Amend DL, Meyerhoff DJ, Tanabe JL, Norman D, Fein G, Weiner MW. Alzheimer Disease: Quantitative H-1 MR Spectroscopic Imaging of Frontoparietal Brain. Radiology. 1998;207(1):91-102.
Gromova EA, Bogdan AA, Kataeva GV, Kotomin IA, Khomenko YuG, Korotkov AD, Trofimova TN, Rassohin VV, BeliakovNA. Peculiarities of functional structures of the brain in HIV infected patients. Luchevaya diagnostica i terapiya. 2016;1:41-48. (In Russ.)
Weissenborn K, Ahl B, Fischer-Wasels D, Hoff J, Hecker H, Burchert W, Kostler H. Correlations between magnetic resonance spectroscopy alterations and cerebral ammonia and glucose metabolism in cirrhotic patients with and without hepatic encephalopathy. Gut. 2007;56(12):1736-1742. https://doi.org/10.1136/gut.2006.110569
Mielke R, Schopphoff HH, Kugel H, Pietrzyk U, Heindel W, Kessler J, Heiss WD. Relation between 1H MR spectroscopic imaging and regional cerebral glucose metabolism in Alzheimer’s disease. Int J Neurosci. 2001;107(3-4):233-245. https://doi.org/10.3109/00207450109150687
O’Neill J, Eberling JL, Schuff N, Jagust W, Reed B, Soto G, Ezekiel F, Klein G, Weiner MW. Method to correlate 1H MRSI and 18FDG-PET. Magn Reson Med. 2000;43(2):244-50. https://doi.org/10.1002/(sici)1522-2594(200002)43:2<244::aid-mrm11>3.3.co

Close metadata